VANCOUVER, BC – TheNewswire - JUNE 27, 2023 – Izotropic Corporation (“Izotropic” or the “Company”) (CSE:IZO) (OTC:IZOZF) (FSE:1R3), a medical device company commercializing IzoView, a 360-degree computed tomography (CT) imaging system designed for breast imaging announced that it has engaged Douglas McKay and Associates (“DMA”) to assist the Company with its communications and financing initiatives.

Subject to necessary approvals from the Canadian Securities Exchange, DMA has been engaged under the following agreement terms:

Agreement Length:

1. 6 (six) months, with an option to extend.  

Remuneration:

1. Monthly fee of $7,000.00 CAD per month that will be deferred until the Company completes its next financing (currently undertaking); and 

2. 400,000 stock options at an exercise price of $0.275 for a 2 (two) year term. The stock options will vest according to the following schedule: 50% of the stock options will vest on September 27th, 2023, and 50% of the stock options on December 27th, 2023; and 

3. 300,000 restricted share units. The restricted share units will vest according to the following schedule: 100,000 shares on August 27th, 2023, 100,000 shares on October 27th, 2023, and 100,000 shares on December 27th, 2023. 

Izotropic had previously engaged DMA in 2020 as part of its awareness building initiatives. DMA was effective at attracting many new shareholders and assisted the Company by introducing several medical professionals and other individuals who participated into 2 (two) separate financings completed in 2020. The Company looks forward to working with DMA again as it moves forwards on its recently announced modified market approval pathway and strategy for FDA market clearance in the USA.

ON BEHALF OF THE BOARD

Mr. Robert Thast, CEO

Cell: 604-220-5031

Contact:

Email: info@izocorp.com

Toll Free: 1-833-IZOCORP ext.1

About Izotropic Corporation

More information about Izotropic Corporation can be found on its website at izocorp.com and by reviewing its profile on SEDAR at sedar.com.

Forward-Looking Statements

This document may contain statements that are "Forward-Looking Statements," which are based upon the current estimates, assumptions, projections, and expectations of the Company's management, business, and its knowledge of the relevant market and economic environment in which it operates. The Company has tried, where possible, to identify such information and statements by using words such as "anticipate," "believe," "envision," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "contemplate" and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words.

These statements are not guarantees of performance and involve risks, including those related to capital requirements and uncertainties that are difficult to control or predict, and as such, they may cause future results of the Company's activity to differ significantly from the content and implications of such statements. Forward-Looking Statements are pertinent only as of the date on which they are made, and the Company undertakes no obligation to update or revise any Forward-Looking Statements to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. Neither the Company nor its shareholders, officers, and consultants shall be liable for any action and the results of any action taken by any person based on the information contained herein, including, without limitation, the purchase or sale of Company securities. Nothing in this document should be deemed to be medical or other advice of any kind. All images are for illustrative purposes only. IzoView is not yet approved for sale.